Clinical Trials

Biogen Trial (REASON)

We are working with Biogen on a phase I trial on a drug that may diminish the function of a gene LRRK2. This gene is the most common genetic cause of Parkinson’s disease and is considered a high genetic risk factor for normal Parkinson's disease which has multiple interrelated causes.

Status: ENROLLING

Microbiome in Parkinson's disease

There has been an escalation of recent research suggesting Parkinson's may be related to the microbiome in the digestive system. The organisms and environment of the gut are called the microbiome. Dr. Tolleson is working with scientists at Oak Ridge National Lab to better understand the microbiome in Parkinson's disease. The study might identify new treatment options. This study compares a cohort of Parkinson’s disease patients, Alzheimer's disease patients, Amyotrophic Lateral Sclerosis patients, and patients free from these diseases to determine the differences in each cohort’s microbiome. Dr. Roberto Fernandez, medical director of the Pat Summitt Clinic, and Dr. Randy Trudell, our expert in Amyotrophic Lateral Sclerosis, are also involved.

Status: DATA ANALYSIS

COPE-PD

This is prospective trial looking at how to better assist palliative care needs in Parkinson’s and Parkinson’s-like conditions for both patients and caregivers. It is being run through the University of Rochester. It is a virtual study not requiring in-person visits. Through at least 2023, it will involve only patients responding to surveys and questionnaires. Afterwards, the study will compare current care to an organized virtual support model where enrolled patients and caregivers will have access to a variety of virtual resources.

Status: ENROLLING
ORCHESTRA PD

This is a phase IIA clinical trial investigating UCB0599, an oral alpha-synuclein misfolding inhibitor, which may hopefully slow disease progression in patients with early Parkinson’s disease. Alpha-synuclein is the protein deposit in Parkinson’s disease and is thought to contribute to causing the disease. This study is being done in conjunction with the Parkinson Study Group (PSG). Study participants must be early in their disease (less than 2 years from diagnosis) and have not started Parkinson’s medication.

Status: Closed for enrollment.